145 related articles for article (PubMed ID: 23508075)
1. Safety testing of epimacular brachytherapy with microperimetry and indocyanine green angiography: 12-month results.
Petrarca R; Richardson M; Douiri A; Nau J; McHugh D; Stangos AN; Jackson TL
Retina; 2013 Jun; 33(6):1232-40. PubMed ID: 23508075
[TBL] [Abstract][Full Text] [Related]
2. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
Jackson TL; Dugel PU; Bebchuk JD; Smith KR; Petrarca R; Slakter JS; Jaffe GJ; Nau JA;
Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
[TBL] [Abstract][Full Text] [Related]
3. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
[TBL] [Abstract][Full Text] [Related]
4. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
[TBL] [Abstract][Full Text] [Related]
5. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.
Petrarca R; Dugel PU; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Retina; 2014 May; 34(5):874-9. PubMed ID: 24169101
[TBL] [Abstract][Full Text] [Related]
6. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
Petrarca R; Dugel PU; Nau J; Slakter JS; Jaffe GJ; Jackson TL
Ophthalmology; 2013 Feb; 120(2):328-33. PubMed ID: 23178157
[TBL] [Abstract][Full Text] [Related]
7. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
Dugel PU; Bebchuk JD; Nau J; Reichel E; Singer M; Barak A; Binder S; Jackson TL;
Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
[TBL] [Abstract][Full Text] [Related]
8. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
[TBL] [Abstract][Full Text] [Related]
9. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
Jackson TL; Desai R; Simpson A; Neffendorf JE; Petrarca R; Smith K; Wittes J; Lewis C; Membrey L; Haynes R; Costen M; Steel DH; Muldrew A; Chakravarthy U;
Ophthalmology; 2016 Jun; 123(6):1287-96. PubMed ID: 27086023
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Octopus perimetry and fluorescein angiography after strontium-90 plaque brachytherapy for subfoveal exudative age related macular degeneration.
Jaakkola A; Vesti E; Immonen I
Br J Ophthalmol; 1998 Jul; 82(7):763-8. PubMed ID: 9924368
[TBL] [Abstract][Full Text] [Related]
11. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
12. One-year results from clinical practice of epimacular strontium-90 brachytherapy for the treatment of subfoveal choroidal neovascularization secondary to AMD.
Zur D; Loewenstein A; Barak A
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):338-43. PubMed ID: 25856820
[TBL] [Abstract][Full Text] [Related]
13. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
14. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results.
Parravano M; Oddone F; Tedeschi M; Chiaravalloti A; Perillo L; Boccassini B; Varano M
Retina; 2010; 30(7):1017-24. PubMed ID: 20224469
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab.
Mathew R; Richardson M; Sivaprasad S
Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653
[TBL] [Abstract][Full Text] [Related]
16. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
17. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration.
Avila MP; Farah ME; Santos A; Duprat JP; Woodward BW; Nau J
Br J Ophthalmol; 2009 Mar; 93(3):305-9. PubMed ID: 19019935
[TBL] [Abstract][Full Text] [Related]
18. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
Yodoi Y; Tsujikawa A; Nakanishi H; Otani A; Tamura H; Ojima Y; Hayashi H; Yoshimura N
Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
[TBL] [Abstract][Full Text] [Related]
19. Correlation between components of newly diagnosed exudative age-related macular degeneration lesion and focal retinal sensitivity.
Hautamäki A; Oikkonen J; Onkamo P; Immonen I
Acta Ophthalmol; 2014 Feb; 92(1):51-8. PubMed ID: 22998103
[TBL] [Abstract][Full Text] [Related]
20. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
Campa C; Hagan R; Sahni JN; Brown MC; Beare NA; Heimann H; Harding SP
Invest Ophthalmol Vis Sci; 2011 Jun; 52(6):3446-51. PubMed ID: 21357390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
